

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: HOGARTH, et al. } Group Art Unit: 1633
Serial No.: 10/517,251 } Examiner: Wehbé, A.M.S.
Filed: December 7, 2004 } Conf. No.: 2961
Atty. File No.: 5644AL-1 }
For: FcγRIIA TRANSGENIC ANIMAL MODEL }
FOR AUTOIMMUNE DISEASE" }
} COMMENTS ON STATEMENT
} OF REASONS FOR ALLOWANCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants wish to comment on the Examiner's reasons for allowance contained within the Notice of Allowability mailed November 23, 2007. Specifically, the Examiner states that the claims have been amended to "indicate that the transgenic mouse spontaneously develops arthritis and systemic lupus erythematosus...." Notice of Allowability, page 7 (emphasis added). Applicants note that allowed claims in fact recite a transgenic mouse "susceptible to spontaneous development of an autoimmune disease selected from the group consisting of arthritis and systemic lupus erythematosus." Accordingly, the claims are not limited to a mouse that develops both arthritis and systemic lupus erythematosus. Rather, the claims recite the spontaneous development of either arthritis or systemic lupus erythematosus.

If the Examiner has any questions regarding this paper, the Examiner is invited to contact the undersigned at 303-863-9700. In the event that any fees are due in connection with this response, please debit Deposit Account No. 19-1970.

Respectfully submitted,

SHERIDAN ROSS P.C.

Dated: January 30, 2008

By: /John C. Stolpa/
John C. Stolpa
Registration No. 57,632
1560 Broadway, Suite 1200
Denver, CO 80202-5141
(303) 863-9700